RXRA and cancer: These effects were significantly attenuated by siRNA knockdown of RXRα indicating that RXRα is a direct target of sulindac, but significantly enhanced by TNFα treatment that was shown to convert Akt signaling to an RXRα-dependent manner in cancer cells.